Skip to content

US · PPCB · BIOTECHNOLOGY

Propanc Biopharma, Inc. (PPCB) intrinsic value and stock valuation

$1.78as of 2026-11-21 · Mkt cap 2.69M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Propanc Biopharma, Inc. DCF and intrinsic value

InvestorsCraft values PPCB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PPCB’s statements →

Propanc Biopharma, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Camberwell, VIC 3124 propanc.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-58.92M
20112025
Free cash flow
-$-410K
20112025
Total equity
$13.9M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-57.28M-$-1.54M-$-1.78M-$-1.99M-$-1.81M
Net income-$-58.92M-$-1.82M-$-2.66M-$-2.66M-$-2.03M
EPSd-$-368.25M————
Operating cash flow-$-410K-$-940K-$-1.11M-$-1.44M-$-1.15M
Capital expenditure-$0.00-$0.00$0.00$0.00$0.00
Free cash flow-$-410K-$-940K-$-1.11M-$-1.44M-$-1.15M
Total assets$19.6M$70K$60K$80K$10K
Total debt$1.73M$950K$550K$1.04M$680K
Net debt$1.71M$930K$540K$1.04M$680K
Total equity$13.9M-$-3.78M-$-3.12M-$-3.02M-$-3.07M
Cash and short-term investments$10K$20K$10K$0.00$0.00
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$20K$20K$0.00$0.00
Gross profit$0.00-$-20K-$-20K-$-10K$0.00
Research and development expenses$220K$250K$250K$260K$230K
Selling, general and administrative expenses$57.1M$1.29M$1.53M$1.73M$1.58M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$57.3M$1.51M$1.76M$1.99M$1.81M
Cost and expenses$57.3M$1.54M$1.78M$1.99M$1.81M
Interest income$0.00$0.00$0.00$10K$0.00
Interest expense$560K$670K$530K$570K$450K
Depreciation and amortization$20K$20K$20K$0.00$0.00
Ebitda-$-58.34M-$-1.26M-$-2.23M-$-2.14M-$-1.69M
Operating income-$-57.28M-$-1.54M-$-1.78M-$-1.99M-$-1.81M
Total other income/expenses, net-$-1.65M-$-410K-$-1.01M-$-720K-$-330K
Income before tax-$-58.92M-$-1.95M-$-2.79M-$-2.71M-$-2.14M
Income tax expense$0.00-$-130K-$-130K-$-50K-$-110K
Net income-$-58.92M-$-1.82M-$-2.66M-$-2.66M-$-2.03M
Weighted average shares outstanding$160K$0.00$0.00$0.00$0.00
Weighted average diluted shares outstanding$160K$0.00$0.00$0.00$0.00
Balance sheet
20252024202320222021
Cash and short-term investments$10K$20K$10K$0.00$0.00
Net receivables$10K$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$8.35M$30K$20K$20K$10K
Property, plant and equipment, net$60K$20K$40K$60K$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$11.3M$50K$40K$70K$10K
Total assets$19.6M$70K$60K$80K$10K
Accounts payable$1.25M$1.21M$970K$940K$1M
Short-term debt$1.58M$890K$530K$1M$680K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$5.58M$3.79M$3.16M$3.06M$3.08M
Long-term debt$150K$60K$20K$40K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$150K$60K$20K$40K$0.00
Capital lease obligations$60K$20K$40K$60K$0.00
Total liabilities$5.73M$3.85M$3.18M$3.11M$3.08M
Common stock$10K$480K$10K$0.00$10K
Retained earnings-$-125.62M-$-66.7M-$-64.68M-$-61.56M-$-58.2M
Accumulated other comprehensive income (loss)$1.32M$1.27M$1.29M$1.23M$1.09M
Total equity$13.9M-$-3.78M-$-3.12M-$-3.02M-$-3.07M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$1.73M$950K$550K$1.04M$680K
Net debt$1.71M$930K$540K$1.04M$680K
Cash flow statement
20252024202320222021
Net income-$-58.92M-$-1.82M-$-2.66M-$-2.66M-$-2.03M
Depreciation and amortization$20K$20K$20K$10K$0.00
Stock-based compensation$4.62M$0.00$0.00$0.00$80K
Change in working capital$1.14M$420K$470K$170K$440K
Accounts receivable-$0.00-$0.00-$0.00$0.00-$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$190K$240K$80K$20K$180K
Net cash provided by operating activities-$-410K-$-940K-$-1.11M-$-1.44M-$-1.15M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$0.00$0.00
Common stock issued$0.00$20K$20K$100K$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$490K$940K$1.11M$1.49M$1.06M
Net change in cash-$-10K$10K$10K$0.00-$-60K
Cash at end of period$10K$20K$10K$0.00$0.00
Operating cash flow-$-410K-$-940K-$-1.11M-$-1.44M-$-1.15M
Capital expenditure-$0.00-$0.00$0.00$0.00$0.00
Free cash flow-$-410K-$-940K-$-1.11M-$-1.44M-$-1.15M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Propanc Biopharma, Inc.

        Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.

        CEO
        James Nathanielsz
        Employees
        2
        Beta
        3.30

        Explore

        Frequently asked questions

        What is the intrinsic value of Propanc Biopharma, Inc. (PPCB)?

        InvestorsCraft does not currently publish an intrinsic value for PPCB. How the IC value is calculated.

        Is PPCB undervalued?

        InvestorsCraft does not publish an undervaluation signal for PPCB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.